The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells

Prostate

Volumn 72, Issue 6, 2012, Pages 612-625

  Fajardo, Alexandra M ^a,b   MacKenzie, Debra A ^b   Ji, Ming ^a   Deck, Lorraine M ^c   Jagt, David L Vander ^a   Thompson, Todd A ^b,d   Bisoffi, Marco ^a,d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

androgen receptor; curcumin analog; oxidative stress; prostate cancer

Indexed keywords

1,5 BIS(2 HYDROXYPHENYL) 1,4 PENTADIEN 3 ONE; ACETYLCYSTEINE; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; DOWN-REGULATION; HUMANS; MALE; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84858748416     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21464     Document Type: Article

References (50)

1. Gao W, Bohl CE, Dalton JT,. Chemistry and structural biology of androgen receptor. Chem Rev 2005; 105 (9): 3352-3370. (Pubitemid 41430813)
2. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308. (Pubitemid 38501396)
3. Klotz L,. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88 (12 Suppl.): 3009-3014. (Pubitemid 30413184)
4. Simmons MN, Klein EA,. Combined androgen blockade revisited: Emerging options for the treatment of castration-resistant prostate cancer. Urology 2009; 73 (4): 697-705.
5. Fitzpatrick JM,. Is hormone ablation still the right choice for advanced prostate cancer? BJU Int 2007; 100 (Suppl 2): 36-39. (Pubitemid 46985611)
6. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C,. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992; 147 (3 Pt 2): 798-803.
7. Sadi MV, Walsh PC, Barrack ER,. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67 (12): 3057-3064.
8. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H,. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000; 7 (7): 997-1007. (Pubitemid 30483479)
9. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS,. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 2009; 15 (1): 39-47.
10. Chen Y, Sawyers CL, Scher HI,. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 (4): 440-448.
11. Knudsen KE, Scher HI,. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15 (15): 4792-4798.
12. Weber WM, Hunsaker LA, Abcouwer SF, Deck LM, Vander Jagt DL,. Anti-oxidant activities of curcumin and related enones. Bioorg Med Chem 2005; 13 (11): 3811-3820. (Pubitemid 40615931)
13. Weber WM, Hunsaker LA, Gonzales AM, Heynekamp JJ, Orlando RA, Deck LM, Vander Jagt DL,. TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin. Biochem Pharmacol 2006; 72 (8): 928-940. (Pubitemid 44374461)
14. Weber WM, Hunsaker LA, Roybal CN, Bobrovnikova-Marjon EV, Abcouwer SF, Royer RE, Deck LM, Vander Jagt DL,. Activation of NFkappaB is inhibited by curcumin and related enones. Bioorg Med Chem 2006; 14 (7): 2450-2461. (Pubitemid 43254754)
15. Mosley CA, Liotta DC, Snyder JP,. Highly active anticancer curcumin analogues. Adv Exp Med Biol 2007; 595: 77-103.
16. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB,. Biological activities of curcumin and its analogues (congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76 (11): 1590-1611.
17. Thompson TA, Gould MN, Burkholder JK, Yang NS,. Transient promoter activity in primary rat mammary epithelial cells evaluated using particle bombardment gene transfer. In Vitro Cell Dev Biol 1993; 29A (2): 165-170. (Pubitemid 23102585)
18. Moinova HR, Mulcahy RT,. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory subunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem 1998; 273 (24): 14683-14689. (Pubitemid 28272751)
19. Dennis MK, Bowles HJ, MacKenzie DA, Burchiel SW, Edwards BS, Sklar LA, Prossnitz ER, Thompson TA,. A multifunctional androgen receptor screening assay using the high-throughput Hypercyt flow cytometry system. Cytometry A 2008; 73 (5): 390-399. (Pubitemid 351614726)
20. Abramoff MD, Magelhaes PJ, Ram SJ,. Image processing with imageJ. Biophotonics Int 2004; 11 (7): 36-42.
21. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G,. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2009; 69 (19): 7689-7695.
22. Ripple MO, Henry WF, Rago RP, Wilding G,. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Canc Inst 1997; 89 (1): 40-48. (Pubitemid 26428076)
23. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chiang T, Chang E, Lee Y, Tsai MY, Chang C, Lee KH,. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002; 45 (23): 5037-5042. (Pubitemid 35278699)
24. Shi Q, Shih CC, Lee KH,. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer Agents Med Chem 2009; 9 (8): 904-912.
25. Zhou J, Geng G, Shi Q, Sauriol F, Wu JH,. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem 2009; 52 (17): 5546-5550.
26. Kung HJ, Evans CP,. Oncogenic activation of androgen receptor. Urol Oncol 2009; 27 (1): 48-52.
27. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS,. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006; 175 (1): 27-34. (Pubitemid 41797079)
28. Muthuramalingam SR, Patel K, Protheroe A,. Management of patients with hormone refractory prostate cancer. Clin Oncol (R Coll Radiol) 2004; 16 (8): 505-516. (Pubitemid 39517657)
29. Van Allen EM, Ryan CJ,. Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol 2009; 19 (3): 315-321.
30. Edwards J, Bartlett JM,. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 2005; 95 (9): 1327-1335. (Pubitemid 40799455)
31. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261. (Pubitemid 46211563)
32. Aggarwal BB,. Prostate cancer and curcumin: Add spice to your life. Cancer Biol Ther 2008; 7 (9): 1436-1440.
33. Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS,. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002; 21 (4): 825-830.
34. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH,. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl 2008; 29 (6): 661-668.
35. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB,. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4 (6): 807-818.
36. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, Camalier RF, Hollingshead MG, Kaur G, Sausville EA, Rickles FR, Snyder JP, Liotta DC, Shoji M,. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004; 12 (14): 3871-3883. (Pubitemid 38798249)
37. Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoli F, Imbriano C,. Curcumin derivatives: Molecular basis of their anti-cancer activity. Biochem Pharmacol 2009; 78 (10): 1305-1315.
38. Ishida J, Ohtsu H, Tachibana Y, Nakanishi Y, Bastow KF, Nagai M, Wang HK, Itokawa H, Lee KH,. Antitumor agents. Part 214: Synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem 2002; 10 (11): 3481-3487.
39. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, Takahashi S, Kato S, Suzuki T, Ishioka C, Iwabuchi Y, Shibata H,. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5 (10): 2563-2571. (Pubitemid 44650921)
40. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C,. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002; 21 (15): 4037-4048. (Pubitemid 34857436)
41. Sheflin L, Keegan B, Zhang W, Spaulding SW,. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 2000; 276 (1): 144-150.
42. Jaiswal AK,. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004; 36 (10): 1199-1207. (Pubitemid 38526313)
43. Burchiel SW, Thompson TA, Lauer FT, Oprea TI,. Activation of dioxin response element (DRE)-associated genes by benzo(a)pyrene 3,6-quinone and benzo(a)pyrene 1,6-quinone in MCF-10A human mammary epithelial cells. Toxicol Appl Pharmacol 2007; 221 (2): 203-214. (Pubitemid 46764801)
44. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, Talalay P,. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci USA 2001; 98 (6): 3404-3409. (Pubitemid 32220858)
45. Katsuoka F, Motohashi H, Engel JD, Yamamoto M,. Nrf2 transcriptionally activates the mafG gene through an antioxidant response element. J Biol Chem 2005; 280 (6): 4483-4490. (Pubitemid 40288614)
46. Breusing N, Grune T,. Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem 2008; 389 (3): 203-209. (Pubitemid 351329027)
47. Szweda PA, Friguet B, Szweda LI,. Proteolysis, free radicals, and aging. Free Radic Biol Med 2002; 33 (1): 29-36. (Pubitemid 34681003)
48. Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS, Chatterjee B,. Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein- regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem 2008; 283 (52): 36474-36485.
49. Koka PS, Mondal D, Schultz M, Abdel-Mageed AB, Agrawal KC,. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: Role of reactive oxygen species. Exp Biol Med (Maywood) 2010; 235 (6): 751-760.
50. Ketola K, Vainio P, Fey V, Kallioniemi O, Iljin K,. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells. Mol Cancer Ther 2010; 9 (12): 3175-3185.